Landscapes / Companies
Incyte Biosciences Japan GK not checked
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
2 approved
Next date
None yet
Drugs
2
in active trials · 6 in all
Trials
2 active
6 since 2021
Drugs2
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Monoclonal antibody |
Incyte · Syndax Pharmaceuticals |
Approved | — | ||
| How it works | An antibody | ||||
| Also tested for | Chronic Graft-versus-host-disease | ||||
| Open drug page | |||||
Monoclonal antibody |
Incyte Corporation · MorphoSys |
Approved | — | ||
| How it works | An antibody | ||||
| Also tested for | Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma | ||||
| Open drug page | |||||
About
- No active trial
- INCB001158, INCB086550, Povorcitinib, Retifanlimab
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 Industry-sponsored drug trials since 2021